image
CorMedix Inc. CRMD
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 10.945
-1.9 %
$ 815 M
Market Cap
43.44
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CRMD stock under the worst case scenario is HIDDEN Compared to the current market price of 10.9 USD, CorMedix Inc. is HIDDEN

CRMD Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CRMD stock under the base case scenario is HIDDEN Compared to the current market price of 10.9 USD, CorMedix Inc. is HIDDEN

CRMD Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one CRMD stock under the best case scenario is HIDDEN Compared to the current market price of 10.9 USD, CorMedix Inc. is HIDDEN

CRMD Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart CRMD

image
1M -44%
6M -11%
1Y 132%
3Y 101%
5Y 87%
All
$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
43.5 M REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 510.62%
5Years 173.65%
7Years 100.88%
10Years 72.23%
-22.4 M OPERATING INCOME
54.34%
Growth Rates
1Year 54.34%
3Years 8.76%
5Years -1.25%
7Years 5.38%
10Years -9.65%
-17.9 M NET INCOME
61.31%
Growth Rates
1Year 61.31%
3Years 14.02%
5Years -1.76%
7Years 8.35%
10Years 1.31%
-50.6 M OPERATING CASH FLOW
-31.78%
Growth Rates
1Year -31.78%
3Years -33.75%
5Years -27.45%
7Years -8.50%
10Years -23.13%
21.2 M INVESTING CASH FLOW
224.44%
Growth Rates
1Year 224.44%
3Years 62.92%
5Years 30.37%
7Years 10.80%
10Years 96.03%
26.3 M FINANCING CASH FLOW
-52.93%
Growth Rates
1Year -52.93%
3Years -14.26%
5Years 0.40%
7Years 3.62%
10Years 12.15%
39.1 M REVENUE
25.22%
Growth Rates
1Year 0.00%
3Years 510.62%
5Years 173.65%
7Years 100.88%
10Years 72.23%
20.1 M OPERATING INCOME
55.58%
Growth Rates
1Year 54.34%
3Years 8.76%
5Years -1.25%
7Years 5.38%
10Years -9.65%
20.6 M NET INCOME
53.32%
Growth Rates
1Year 61.31%
3Years 14.02%
5Years -1.76%
7Years 8.35%
10Years 1.31%
19.7 M OPERATING CASH FLOW
451.53%
Growth Rates
1Year -31.78%
3Years -33.75%
5Years -27.45%
7Years -8.50%
10Years -23.13%
-195 K INVESTING CASH FLOW
35.95%
Growth Rates
1Year 224.44%
3Years 62.92%
5Years 30.37%
7Years 10.80%
10Years 96.03%
6.09 M FINANCING CASH FLOW
-46.01%
Growth Rates
1Year -52.93%
3Years -14.26%
5Years 0.40%
7Years 3.62%
10Years 12.15%
Balance Sheet CorMedix Inc.
image
Current Assets 115 M
Cash & Short-Term Investments 51.7 M
Receivables 51.7 M
Other Current Assets 11.2 M
Non-Current Assets 4.27 M
Long-Term Investments 0
PP&E 2.32 M
Other Non-Current Assets 1.95 M
43.49 %43.46 %9.45 %Total Assets$118.8m
Current Liabilities 33.8 B
Accounts Payable 1.72 M
Short-Term Debt 168 K
Other Current Liabilities 33.8 B
Non-Current Liabilities 349 K
Long-Term Debt 349 K
Other Non-Current Liabilities 0
99.99 %Total Liabilities$33.8b
EFFICIENCY
Earnings Waterfall CorMedix Inc.
image
Revenue 43.5 M
Cost Of Revenue 3.19 M
Gross Profit 40.3 M
Operating Expenses 62.6 M
Operating Income -22.4 M
Other Expenses -4.43 M
Net Income -17.9 M
50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)43m(3m)40m(63m)(22m)4m(18m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
92.66% GROSS MARGIN
92.66%
Averages
1Year 92.66%
3Years 62.32%
5Years 44.66%
7Years 28.46%
10Years 14.90%
-51.43% OPERATING MARGIN
-51.43%
Averages
1Year -51.43%
3Years -15623.78%
5Years -14733.46%
7Years -12476.29%
10Years -11630.58%
-41.24% NET MARGIN
-41.24%
Averages
1Year -41.24%
3Years -15150.38%
5Years -13886.71%
7Years -11639.60%
10Years -11115.25%
-0.02% ROE
-0.02%
Averages
1Year -0.02%
3Years -18.43%
5Years -6.74%
7Years -1.47%
10Years -18.04%
-15.09% ROA
-15.09%
Averages
1Year -15.09%
3Years -39.81%
5Years -41.00%
7Years -57.61%
10Years -81.02%
0.06% ROIC
0.06%
Averages
1Year 0.06%
3Years -40.95%
5Years -43.16%
7Years -75.28%
10Years -117.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CorMedix Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -17.9 M
Depreciation & Amortization 310 K
Capital Expenditures -116 K
Stock-Based Compensation 6.13 M
Change in Working Capital -39.4 M
Others 59.8 B
Free Cash Flow -50.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CorMedix Inc.
image
CRMD has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership CorMedix Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.57 M USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
15 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive? CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 1 week ago
CorMedix Analyst Says Investors Could Be Further Rewarded Last week, CorMedix Inc. CRMD said one of its large dialysis organization (LDO) customers has started ordering, with implementation planned for the second half of 2025. benzinga.com - 3 weeks ago
CorMedix Seems Significantly Undervalued CorMedix offers high upside potential with DefenCath, the only FDA-approved catheter lock solution for CRBSI, and a strong financial position. My DCF model shows a base-case fair value of $26.2 per share, representing 110% upside; the options market also signals bullish sentiment. Key risks include reliance on a single product and high market share uncertainty, so I keep my position size small and avoid options due to illiquidity and high premiums. seekingalpha.com - 3 weeks ago
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday. benzinga.com - 3 weeks ago
CorMedix Inc. Announces Pricing of Public Offering of Common Stock BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock. The total gross proceeds from the offering to the Company are expected to be approximately $85 million. In addition, CorMedix granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 3 weeks ago
CorMedix Inc. Announces Proposed Public Offering of Common Stock BERKELEY HEIGHTS, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it intends to offer and sell $85.0 million of shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by CorMedix. In addition, CorMedix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. globenewswire.com - 4 weeks ago
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength? CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 1 month ago
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug, DefenCath. investors.com - 1 month ago
CorMedix inc. Announces Customer Implementation BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025. globenewswire.com - 1 month ago
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis market. seekingalpha.com - 1 month ago
CorMedix: Exceeding Expectations CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth. seekingalpha.com - 1 month ago
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025. globenewswire.com - 1 month ago
8. Profile Summary

CorMedix Inc. CRMD

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 815 M
Dividend Yield 0.00%
Description CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Contact 300 Connell Drive, Berkeley Heights, NJ, 07922 https://www.cormedix.com
IPO Date May 13, 2010
Employees 64
Officers Dr. Tushar Mukherjee Senior Vice President & Head of Technical Operations Donna Ucci Senior Vice President & Head of Global Quality Dr. Matthew T. David M.D. Executive Vice President & Chief Financial Officer Ms. Elizabeth Masson-Hurlburt B.A. Executive Vice President and Chief Clinical Strategy & Operations Officer Ms. Kaufman Beth Zelnick Esq. EVice President, Chief Legal, Compliance Officer & Corporate Secretary Ms. Erin Mistry Executive Vice President & Chief Commercial Officer Mr. Joseph Todisco MBA Chief Executive Officer & Director